RxDoctor Payments Data

Zachary Curtis

Nurse Practitioner · Athens, ALNPI 1003404856

Payments from drug & device makers

$1,339in general payments, 2019–2025

Across 52 payments — averaging $25.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$382
  • Sumitomo Pharma America, Inc.$349
  • Antares Pharma, Inc.$185
  • Pfizer$97
  • Halozyme Inc$57
  • ABC Home Medical Supply, Inc.$50
  • plus $219 from 9 others

What the payments were for

  • Travel & lodging$38228%
  • Food & beverage$95772%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic5$382
Sumitomo Pharma America, Inc.21$349
Antares Pharma, Inc.7$185
Pfizer5$97
Halozyme Inc2$57
ABC Home Medical Supply, Inc.2$50
180 Medical, Inc.2$47
Otsuka America Pharmaceutical, Inc.1$30
Hollister Incorporated1$26
Olympus America Inc.1$25
Myriad Genetic Laboratories, Inc.1$24
Axonics, Inc.1$19
Solventum Corporation1$18
Tolmar, Inc.1$17
Boston Scientific1$15

How this compares

$1,339 in reported general payments places this provider in the 75th percentile of 1,505 nurse practitioner providers in Alabama.

See all nurse practitioner providers in Alabama

Medicare billing

Part B allowed, 2024
$81,448
Medicare patients
405
Services billed
2,936

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron85$69,616
MyrbetriqMirabegron16$13,228
XyostedTestosterone Enanthate15$12,638
Tamsulosin Hcl478$8,338
Estradiol81$5,961
Methenamine Hippurate47$4,001
Finasteride202$3,075
Testosterone17$1,876
Silodosin14$1,302
Cefdinir69$1,222
Testosterone Cypionate21$795
Dutasteride24$701
Doxycycline Monohydrate29$652
Tadalafil25$650
Alfuzosin Hcl ErAlfuzosin Hcl18$478

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$349$69,61685 claims
Antares Pharma, Inc.Xyosted$185$12,63815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,505 nurse practitioner providers in Alabama.

Other nurse practitioner in Athens

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →